Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Raily Aesthetic Medicine International Holdings Limited ( (HK:2135) ) has provided an announcement.
Raily Aesthetic Medicine International Holdings Limited has updated investors on a change in the planned use of the remaining HK$7.6 million in net proceeds from its recent rights issue. Originally earmarked mainly for registration filing and clinical trials with China’s NMPA, these unutilised funds will now cover a broader range of activities tied to NMPA approval, including research and development, sample production and testing, and equipment procurement.
The board said the shift reflects a more comprehensive view of the multi-stage registration process required to bring aesthetic medical equipment to market in China, aiming to ensure its products meet regulatory requirements and improve the chances of successful approval. The company expects to deploy all remaining proceeds by 31 March 2027, with no other changes to the allocation of rights issue funds, signalling continued investment in regulatory and product development capabilities critical to its long-term growth strategy.
More about Raily Aesthetic Medicine International Holdings Limited
Raily Aesthetic Medicine International Holdings Limited operates in the aesthetic medical industry, focusing on the development and registration of aesthetic medical equipment products in mainland China. The group’s activities include product research and development, clinical trials, sample production and testing, and procurement of specialised equipment to meet regulatory standards and support commercialisation.
Average Trading Volume: 377,720
Technical Sentiment Signal: Sell
Current Market Cap: HK$78.55M
For detailed information about 2135 stock, go to TipRanks’ Stock Analysis page.